197 related articles for article (PubMed ID: 10136564)
1. Retrospective analysis of formulary restriction demonstrates significant cost savings.
Wetmore RW; Jennings RH
Hosp Formul; 1991 Nov; 26 Suppl D():30-2. PubMed ID: 10136564
[TBL] [Abstract][Full Text] [Related]
2. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
Quercia RA; Chow MS; Jay GT; Quintiliani R
Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary education ensures successful formulary conversion.
Barfield PS; Amerson AB
Hosp Formul; 1991 Nov; 26 Suppl D():28-9. PubMed ID: 10136563
[TBL] [Abstract][Full Text] [Related]
4. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
[No Abstract] [Full Text] [Related]
5. Criteria-based DUE aids in selection of preferred agent.
Drea EJ
Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562
[TBL] [Abstract][Full Text] [Related]
6. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
Coppola P
Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
[TBL] [Abstract][Full Text] [Related]
7. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist.
Berkowitz HS
Am J Hosp Pharm; 1992 Jan; 49(1):134-5. PubMed ID: 1349201
[No Abstract] [Full Text] [Related]
8. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
Kitrenos JG; Brown DR; Letting DJ; Rotella DL
Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
[TBL] [Abstract][Full Text] [Related]
9. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
Oh T; Franko TG
Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
[TBL] [Abstract][Full Text] [Related]
10. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
Segal R; Oh T; Ben-Joseph R; Russell WL
Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
[TBL] [Abstract][Full Text] [Related]
11. Multi-purpose evaluation of H2-antagonist usage.
Gianarkis D
Hosp Formul; 1992 May; 27(5):527-30, 532. PubMed ID: 10117769
[TBL] [Abstract][Full Text] [Related]
12. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
13. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary.
Calvo MV; Fruns I; DomÃnguez-Gil A
Am J Hosp Pharm; 1990 Sep; 47(9):2002-6. PubMed ID: 1977316
[TBL] [Abstract][Full Text] [Related]
14. Antiulcer therapy: an exercise in formulary management.
Foulke GE; Siepler J
J Clin Gastroenterol; 1990; 12 Suppl 2():S64-8. PubMed ID: 1978846
[TBL] [Abstract][Full Text] [Related]
15. Experience with a two-tiered therapeutic interchange policy.
Rich DS
Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
Chase SL; Peterson AM; Wordell CJ
Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966
[TBL] [Abstract][Full Text] [Related]
17. Cost savings achieved through cephalosporin use review and restriction.
Dzierba SH; Reilly RT; Caselnova DA
Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
[TBL] [Abstract][Full Text] [Related]
18. Gastroesophageal reflux and histamine2 antagonists.
Bell SG
Neonatal Netw; 2003; 22(2):53-7. PubMed ID: 12696725
[No Abstract] [Full Text] [Related]
19. Pharmacy intern intervention to reduce costs associated with histamine H2-antagonist therapy.
Algozzine GJ; Sprenger RL; Caselnova DA; Proper P
Am J Hosp Pharm; 1989 Jun; 46(6):1183-4. PubMed ID: 2568750
[No Abstract] [Full Text] [Related]
20. Therapeutic substitution of cimetidine for nizatidine was not associated with an increase in healthcare utilization.
Good CB; Fultz SL; Trilli L; Etchason J
Am J Manag Care; 2000 Oct; 6(10):1141-6. PubMed ID: 11184669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
